Rocket Pharmaceuticals (RCKT) Free Cash Flow (2014 - 2026)

Rocket Pharmaceuticals has reported Free Cash Flow for 13 years, with the latest figure at -$45.5 million in Q1 2026.

• Quarterly Free Cash Flow rose 18.54% year-over-year to -$45.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$180.1 million (up 15.26% YoY) and the FY2025 annual result came in at -$190.5 million, up 11.66% from the prior year.
• Free Cash Flow fell to -$45.5 million in Q1 2026 per RCKT's latest filing, from -$34.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$34.9 million in Q4 2025 and troughed at -$59.4 million in Q1 2023.
• A 5-year average of -$49.6 million and a median of -$50.3 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 67.32% in 2022, then jumped 33.54% in 2025.
• Over 5 years, Free Cash Flow stood at -$52.8 million in 2022, then grew by 16.41% to -$44.1 million in 2023, then retreated by 19.12% to -$52.5 million in 2024, then surged by 33.54% to -$34.9 million in 2025, then sank by 30.26% to -$45.5 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$45.5 million, -$34.9 million, and -$50.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.